Gregg Sando

Chairman of the Board, Non-Executive Director

linkedin Logo

Skills & Competencies

Gregg provides years of experience in managing a biotech venture from start-up through to advanced stages of drug development, raising over $150 mln in equity and grant funding from diverse sources to build a company with regulated operations in the USA, UK, Germany and Switzerland. With his hands-on experience in the planning and management of pre-clinical, clinical, manufacturing and marketing activities, Gregg provides advice and perspective to Jellagen’s senior management team across of a range of business activities. His scientific training is firmly grounded in biochemistry and clinical immunology and balanced with an MBA in corporate finance. His international investment banking experience enables Gregg to provide the company with an expert view on private and public financing strategies while ensuring the Board focuses on building shareholder value within a responsible corporate governance approach.

Gregg founded one of the first cancer immunotherapy biotechs in 2005 and has pioneered the commercialisation of innovative T cell therapies for oncology and infectious diseases.

He studied biochemistry at Harvard and then received an MBA from the University of Chicago.  His business career started on Wall Street with Merrill Lynch followed by a move to Morgan Stanley in London.  Gregg went on to manage a highly successful global financial institutions practice at UBS and then joined Deutsche Bank to help build their investment banking activities on a global basis.  Returning to his lifelong passion for science, Gregg left investment banking in 2004 and entered the MSc Immunology postgraduate programme at the Imperial College London medical school.  His research work focused on the therapeutic management of immune stimulation and inhibition pathways which provided the basis for the launch of his cancer immunotherapy company, backed by the Wellcome Trust and venture capital investors.

Gregg is also an investor, adviser and Board Director in several start-up life sciences companies as well as a mentor for young entrepreneurs launching biotech start-ups.